sorafenib has been researched along with methotrexate in 12 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | sorafenib (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Luzzio, FA; Monsen, PJ | 1 |
| Xu, Z; Zhang, L | 1 |
| El-Subbagh, HI; Ghaly, MA; Maarouf, AR; Sabry, MA | 1 |
| Hagström, MV; Hirvonen, JT; Kaasalainen, MH; Mäkilä, EM; Salonen, JJ; Santos, HA; Wang, CF | 1 |
| Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S | 1 |
| Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
| Orbach, D; Penel, N; Ryckewaert, T | 1 |
| Errani, C; Mavrogenis, AF; Takahama, T; Tanaka, Y; Tsukamoto, S | 1 |
| Jiang, J; Lai, L; Liu, X; Sun, B; Wang, X; Xiong, J; Yao, Y; Zhang, X | 1 |
4 review(s) available for sorafenib and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship | 2019 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
Topics: Doxorubicin; Fibromatosis, Aggressive; Humans; Hydroxyurea; Imatinib Mesylate; Methotrexate; Sorafenib; Vinorelbine; Watchful Waiting | 2023 |
8 other study(ies) available for sorafenib and methotrexate
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Antiangiogenic Activity and Chemical Derivatization of the Neurotoxic Acetogenin Annonacin Isolated from Asimina triloba.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Asimina; Capillaries; Fruit; Furans; In Vitro Techniques; Lactones; Molecular Structure; Plant Extracts; Rats; Seeds; Structure-Activity Relationship | 2018 |
New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Folic Acid Antagonists; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles | 2022 |
Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Delayed-Action Preparations; Drug Delivery Systems; Endocytosis; Humans; Methotrexate; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Porosity; Silicon; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity | 2015 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment | 2016 |
[Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
Topics: Adult; Age Factors; Antineoplastic Agents; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Vinblastine | 2020 |
Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Copper; CTLA-4 Antigen; DNA Copy Number Variations; Humans; Imatinib Mesylate; Liver Neoplasms; Methotrexate; Prognosis; Sorafenib; Tumor Microenvironment | 2022 |